← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Battelle Centers/Pub Hlth Res & Evaluatn
Columbus, OH
$409,684,583
Total funding
59
Grants
Funding over time
peak $52.8M · FY2006–25$100M$75M$50M$25M$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$409,336,503 · 57
FDA$348,080 · 2
By mechanism
N01$376,835,983 · 23
R01$22,570,530 · 17
R21$4,280,377 · 11
N02$3,247,026 · 2
U10$1,755,348 · 1
R03$423,803 · 2
Investigators at Battelle Centers/Pub Hlth Res & Evaluatn
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Largest grants
TAS::75 0872::TAS CHILDHOOD OBESITY (0-8470187)$22,750,000
N01 · FY2010 · HL
Studies to Evaluate the Toxic Carcinogenic Potential of Test Agents$15,176,338
N01 · FY2010 · ES
Studies to Evaluate the Toxic Carcinogenic Potential of Test Agents$10,939,975
N01 · FY2009 · ES
Task X14: Evaluation of Ebola Vaccines$8,942,639
N01 · FY2015 · AI
Studies to evaluate the tox and carcinogentic potential of test articles$7,300,000
N01 · FY2010 · ES
MANUFACTURING OF PLASMID AND VECTOR AND GLP DOSE-ESCALATION TOXICOLOGY STUDIES$7,111,272
N01 · FY2025 · DA
Task V05: Development of Assays and Reagents for Coronavirus Vaccines$7,094,023
N01 · FY2020 · AI
Task V12: Clinical Sample Testing for SARS-CoV-2 Vaccine Candidates$6,398,512
N01 · FY2020 · AI
Task V11: General Safety Toxicity Testing, SARS-CoV-2$6,134,108
N01 · FY2024 · AI
Task B02: Determination of Doxycycline and Ciprofloxacin Efficacy in the Cynomolgus Macaque Model of Pneumonic Tularemia$5,087,873
N01 · FY2018 · AI
Short-term Transcriptomic Studies of 1,2-Dichlorobenzene and 1,4-Dichlorobenzene following Whole-body Inhalation Exposure in Rats and Mice$4,929,913
N01 · FY2025 · ES
Studies to Evaluate the Toxic Carcinogenic Potential of Test Agents$4,864,318
N01 · FY2008 · ES
Task B08: Development and Use of a Non-Human Primate Model of SARS-CoV-2 Infection$4,821,458
N01 · FY2020 · AI
Task X18: Evaluation of Filovirus Vaccines$4,518,280
N01 · FY2016 · AI
CHEMISTRY SUPPORT SERVICES TO THE ENVIRONMENTAL TOXICOLOGY PROGRAM$4,350,273
N01 · FY2008 · ES
Chemistry Services for the NTP$4,080,825
N01 · FY2016 · ES
Task V03: Immunogenicity and Efficacy Testing of Medical Countermeasures (Vaccines and Other Biologics) against BSL-4 Pathogens in Non-Human Primates$4,017,825
N01 · FY2020 · AI
Studies to Evaluate the Toxic Carcinogenic Potential of Test Agents$3,906,791
N01 · FY2011 · ES
trans-Resveratrol (RES) in Laboratory Animals for the National Toxicology Program$3,844,989
N01 · FY2013 · ES
Task X8: Efficacy Testing of Filovirus Vaccines in Non-Human Primates$3,511,999
N01 · FY2016 · AI